Recombinant Human WNT5A(Gln38-Lys380) was expressed in CHO.
Predicted N Terminal:
Asn44 & No results obtained: Gln38 predicted
Lyophilized from a 0.2 μm filtered solution in PBS, EDTA and CHAPS with BSA as a carrier protein.
Measured by its ability to inhibit Wnt-3a-induced alkaline phosphatase production by MC3T3‑E1 mouse preosteoblast cells. The ED50 for this effect is typically 0.1-0.5 µg/mL, in the presence of 5 ng/mL rmWnt-3a.
Predicted Molecular Mass: 38 kDa;SDS-PAGE: 45 kDa, reducing conditions.
<1.0 EU per 1 μg of the protein by the LAL method.
>80%, by SDS-PAGE under reducing conditions and visualized by silver stain
Avoid repeated freeze-thaw cycles.12 months from date of receipt, -20 to -70 centigrade as supplied.1 month, 2 to 8 centigrade under sterile conditions after reconstitution.3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.